Telehealth Helps Avoid Delay in Breast Cancer Treatment amid Coronavirus Outbreak
The coronavirus outbreak has affected screening, diagnosis, treatment, and follow-up care for breast cancer. This is why the HER2 breast cancer test market is expanding in a staggered manner during the ongoing pandemic. Many individuals are fearing the contraction of the novel infection, leading to postponement and cancellation of treatments and screening. Nevertheless, telehealth services and mobile apps hold promising potentials to avoid delay in treatment of potential patients.
Since many countries have lifted their stay-at-home orders and allowed businesses to re-open, revenue flow is anticipated to grow in the HER2 breast cancer test market. Healthcare providers are extending their arms to provide essential and critical services to improve the patient quality of life during the ongoing pandemic.
Inaccurate HER2 Test Results with IHC Affect Market Growth
The HER2 breast cancer test market is expected to reach US$ 627.7 Mn by 2031. Immunohistochemistry (IHC) is being publicized as the gold standard for HER2 breast cancer testing. However, it has been found that some HER2 test results may be inaccurate, as different labs have different rules for classifying positive and negative HER2 status. Such findings are anticipated to affect market growth.
Inaccurate HER2 test results may deprive women diagnosed with breast cancer of proper care and treatment. Hence, healthcare providers in the HER2 breast cancer test market are increasing awareness about multiple reviewing of HER2 test results from more than one pathologist to attain certainty in outcomes.
FISH Test V/S IHC Test: Which is Better?
The FISH (Fluorescence In Situ Hybridization) test is not as widely available as compared to IHC. However, it has been found that FISH test in more accurate and reliable than IHC. In many cases, a lab will do the IHC test first and order FISH test only if the IHC results do not clearly show whether the cells are HER2-positive or negative.
The HER2 breast cancer test market is expected to register a CAGR of 6.5% during the forecast period. The growing popularity of FISH test helps to map the genetic material in a person’s cells. This test is used to visualize specific genes or portions of genes.
HER2 Testing Becoming Routine Practice for Newly Diagnosed Breast Cancer
IHC and FISH tests are gaining popularity for proper diagnosis, treatment, and follow-up care for HER2 breast cancer. HER2 testing is becoming a routine practice for newly diagnosed breast cancer in pathology. Bright-field in situ hybridization such as chromogenic in situ hybridization (CISH) has an advantage, since it allows histologic evaluation of tumors, utilizes ordinary microscope, can be fully automated, and leaves permanent signals for archival storage.
The CISH test is emerging as a suitable alternative to FISH test. Such trends are contributing to the growth of the HER2 breast cancer test market. For uniformity in accuracy and reproducibility of HER2 testing in breast cancer, the ASCO (American Society of Clinical Oncology) has released guidelines for the interpretation of HER2 status.
Analysts’ Viewpoint
Virtual medical appointments hold potentials in increasing healthcare utilization post the COVID-19 period. Since HER2 testing is associated with inaccuracy in results, healthcare providers, and labs in the HER2 breast cancer test market should adhere to the guidelines issued by the CAP (College of American Pathologists) to address a wide range of pre-analytic, analytic, and post-analytic variables. Apart from testing, companies in the HER2 breast cancer test market should unlock growth opportunities in increasing the availability of treatments such as enhertu, Herceptin, and kadcyla to improve patient outcomes. IHC test and FISH test remain the gold standard for efficient diagnosis of HER2 breast cancer.
HER2 Breast Cancer Test Market: Overview
HER2 Breast Cancer Test Market: Key Drivers
Market Segmentation: HER2 Breast Cancer Test Market
Regional Overview: HER2 Breast Cancer Test Market
Major Players
HER2 Breast Cancer Test Market Snapshot
|
Attribute |
Detail |
|
Market Size Value in 2020 |
US$ 313.4 Mn |
|
Market Forecast Value in 2031 |
US$ 627.7 Mn |
|
Growth Rate (CAGR) |
6.5% |
|
Forecast Period |
2021–2031 |
|
Historical Data Available for |
2017–2019 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
HER2 Breast Cancer Test Market - Segmentation
TMR’s study on the global HER2 breast cancer test market includes information divided into six segments: test type, end-user, and region. Changing industry trends and other market dynamics associated with these segments of the global HER2 breast cancer test market are discussed in detail.
| Test Type |
|
| End-user |
|
| Region |
|
HER2 breast cancer test market is expected to reach US$ 627.7 Mn by 2031
HER2 breast cancer test market is expected to register a CAGR of 6.5% during 2021-2031
HER2 breast cancer test market is driven by rise in prevalence of breast cancer across the globe
The end-use segments in HER2 breast cancer test market are hospitals and diagnostic laboratories.
Key players operating in the global market include Abbott Molecular Inc., Biogenex Laboratories, Inc., Leica Biosystems, Roche, Agilent Technologies
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Global HER2 Breast Cancer Test Market Forecast
4.3. Global HER2 Breast Cancer Test Market Outlook
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
5. Key Insights
5.1. Revenue Model
5.2. Pricing Analysis
5.3. COVID-19 Impact Analysis
6. Global HER2 Breast Cancer Test Market Analysis, by Test Type
6.1. Introduction
6.2. Global HER2 Breast Cancer Test Market Value Share Analysis, by Test Type
6.3. Global HER2 Breast Cancer Test Market Forecast, by Test Type
6.3.1. Immunohistochemistry (IHC)
6.3.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
6.4. Global HER2 Breast Cancer Test Market Analysis, by Test Type
6.5. Global HER2 Breast Cancer Test Market Attractiveness Analysis, by Test Type
7. Global HER2 Breast Cancer Test Market Analysis, by End-user
7.1. Introduction
7.2. Global HER2 Breast Cancer Test Market Value Share Analysis, by End-user
7.3. Global HER2 Breast Cancer Test Market Forecast, by End-user
7.3.1. Hospitals
7.3.2. Diagnostic Laboratories
7.4. Global HER2 Breast Cancer Test Market Analysis, by End-user
7.5. Global HER2 Breast Cancer Test Market Attractiveness Analysis, by End-user
8. Global HER2 Breast Cancer Test Market Analysis, by Region
8.1. Introduction
8.2. Global HER2 Breast Cancer Test Market Value Share Analysis, by Region
8.3. Global HER2 Breast Cancer Test Market Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
9. North America HER2 Breast Cancer Test Market Analysis
9.1. North America HER2 Breast Cancer Test Market Overview
9.2. North America HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Country
9.2.1. U.S.
9.2.2. Canada
9.3. North America HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Test Type
9.4. North America HER2 Breast Cancer Test Market Forecast, by Test Type
9.4.1. Immunohistochemistry (IHC)
9.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
9.5. North America HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by End-user
9.6. North America HER2 Breast Cancer Test Market Forecast, by End-user
9.6.1. Hospitals
9.6.2. Diagnostic Laboratories
10. Europe HER2 Breast Cancer Test Market Analysis
10.1. Europe HER2 Breast Cancer Test Market Overview
10.2. Europe HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Country/Sub-region
10.2.1. Germany
10.2.2. U.K.
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Europe HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Test Type
10.4. Europe HER2 Breast Cancer Test Market Forecast, by Test Type
10.4.1. Immunohistochemistry (IHC)
10.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
10.5. Europe HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by End-user
10.6. Europe HER2 Breast Cancer Test Market Forecast, by End-user
10.6.1. Hospitals
10.6.2. Diagnostic Laboratories
11. Asia Pacific HER2 Breast Cancer Test Market Analysis
11.1. Asia Pacific HER2 Breast Cancer Test Market Overview
11.2. Asia Pacific HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.2.1. China
11.2.2. Japan
11.2.3. India
11.2.4. Australia & New Zealand
11.2.5. Rest of Asia Pacific
11.3. Asia Pacific HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Test Type
11.4. Asia Pacific HER2 Breast Cancer Test Market Forecast, by Test Type
11.4.1. Immunohistochemistry (IHC)
11.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
11.5. Asia Pacific HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by End-user
11.6. Asia Pacific HER2 Breast Cancer Test Market Forecast, by End-user
11.6.1. Hospitals
11.6.2. Diagnostic Laboratories
12. Latin America HER2 Breast Cancer Test Market Analysis
12.1. Latin America HER2 Breast Cancer Test Market Overview
12.2. Latin America HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Country/Sub-region
12.2.1. Brazil
12.2.2. Mexico
12.2.3. Rest of Latin America
12.3. Latin America HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by Test Type
12.4. Latin America HER2 Breast Cancer Test Market Forecast, by Test Type
12.4.1. Immunohistochemistry (IHC)
12.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
12.5. Latin America HER2 Breast Cancer Test Market Value Share and Attractiveness analysis, by End-user
12.6. Latin America HER2 Breast Cancer Test Market Forecast, by End-user
12.6.1. Hospitals
12.6.2. Diagnostic Laboratories
13. Middle East & Africa HER2 Breast Cancer Test Market Analysis
13.1. Middle East & Africa HER2 Breast Cancer Test Market Overview
13.2. Middle East & Africa HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.2.1. GCC Countries
13.2.2. South Africa
13.2.3. Rest of Middle East & Africa
13.3. Middle East & Africa HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by Test Type
13.4. Middle East & Africa HER2 Breast Cancer Test Market Forecast, by Test Type
13.4.1. Immunohistochemistry (IHC)
13.4.2. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)
13.5. Middle East & Africa HER2 Breast Cancer Test Market Value Share and Attractiveness Analysis, by End-user
13.6. Middle East & Africa HER2 Breast Cancer Test Market Forecast, by End-user
13.6.1. Hospitals
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2019
14.3. Company Profiles
14.3.1. Abbott Laboratories
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Strategic Overview
14.3.2. BioGenex
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Strategic Overview
14.3.3. Agilent Technologies, Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Strategic Overview
14.3.4. Leica Biosystems
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Strategic Overview
14.3.5. Roche
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Strategic Overview
14.3.6. Mylab Discovery Solutions Pvt. Ltd.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Strategic Overview
List of Tables
Table 01: Global HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by Test Type, 2017–2031
Table 02: Global HER2 Breast Cancer Test Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 03: North America HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast, by Country, 2017–2031
Table 04: North America HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by Test Type, 2017–2031
Table 05: North America HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: Europe HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 07: Europe HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by Test Type, 2017–2031
Table 08: Europe HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Asia Pacific HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Asia Pacific HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by Test Type, 2017–2031
Table 11: Asia Pacific HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Latin America HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Latin America HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by Test Type, 2017–2031
Table 14: Latin America HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 15: Middle East & Africa HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Middle East & Africa HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by Test Type, 2017–2031
Table 17: Middle East & Africa HER2 Breast Cancer Test Market Size (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global HER2 Breast Cancer Test Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global HER2 Breast Cancer Test Market Value Share, by Test Type (2020)
Figure 03: Global HER2 Breast Cancer Test Market Value Share, by End-user (2020)
Figure 04: Global HER2 Breast Cancer Test Market Value Share, by Region (2020)
Figure 05: Global HER2 Breast Cancer Test Market Value Share Analysis, by Test Type, 2020 and 2031
Figure 06: Global HER2 Breast Cancer Test Market Revenue (US$ Mn), by Immunohistochemistry (IHC), 2017–2031
Figure 07: Global HER2 Breast Cancer Test Market Revenue (US$ Mn), by Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH), 2017–2031
Figure 08: Global HER2 Breast Cancer Test Market Attractiveness Analysis, by Test Type, 2021–2031
Figure 09: Global HER2 Breast Cancer Test Market Value Share Analysis, by Region, 2020 and 2031
Figure 10: Global HER2 Breast Cancer Test Market Attractiveness, by Region, 2021-2031
Figure 11: North America HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 12: North America HER2 Breast Cancer Test Market Value Share (%), by Country, 2020 and 2031
Figure 13: North America HER2 Breast Cancer Test Market Attractiveness, by Country, 2021–2031
Figure 14: North America HER2 Breast Cancer Test Market Value Share Analysis, by Test Type, 2020 and 2031
Figure 15: North America HER2 Breast Cancer Test Market Attractiveness, by Test Type, 2021–2031
Figure 16: North America HER2 Breast Cancer Test Market Value Share Analysis, by End-user, 2020 and 2031
Figure 17: North America HER2 Breast Cancer Test Market Attractiveness, by End-user, 2021–2031
Figure 18: Europe HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 19: Europe HER2 Breast Cancer Test Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 20: Europe HER2 Breast Cancer Test Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 21: Europe HER2 Breast Cancer Test Market Value Share Analysis, by Test Type, 2020 and 2031
Figure 22 Europe HER2 Breast Cancer Test Market Attractiveness, by Test Type, 2021–2031
Figure 23: Europe HER2 Breast Cancer Test Market Value Share Analysis, by End-user, 2020 and 2031
Figure 24: Europe HER2 Breast Cancer Test Market Attractiveness, by End-user, 2021–2031
Figure 25: Asia Pacific HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 26: Asia Pacific HER2 Breast Cancer Test Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 27: Asia Pacific HER2 Breast Cancer Test Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 28: Asia Pacific HER2 Breast Cancer Test Market Value Share Analysis, by Test Type, 2020 and 2031
Figure 29: Asia Pacific HER2 Breast Cancer Test Market Attractiveness, by Test Type, 2021–2031
Figure 30: Asia Pacific HER2 Breast Cancer Test Market Value Share Analysis, by End-user, 2020 and 2031
Figure 31: Asia Pacific HER2 Breast Cancer Test Market Attractiveness, by End-user, 2021–2031
Figure 32: Latin America HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 33: Latin America HER2 Breast Cancer Test Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 34: Latin America HER2 Breast Cancer Test Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 35: Latin America HER2 Breast Cancer Test Market Value Share Analysis, by Test Type, 2020 and 2031
Figure 36: Latin America HER2 Breast Cancer Test Market Attractiveness, by Test Type, 2021–2031
Figure 37: Latin America HER2 Breast Cancer Test Market Value Share Analysis, by End-user, 2020 and 2031
Figure 38: Latin America HER2 Breast Cancer Test Market Attractiveness, by End-user, 2021–2031
Figure 39: Middle East & Africa HER2 Breast Cancer Test Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 40: Middle East & Africa HER2 Breast Cancer Test Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 41: Middle East & Africa HER2 Breast Cancer Test Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 42: Middle East & Africa HER2 Breast Cancer Test Market Value Share Analysis, by Test Type, 2020 and 2031
Figure 43: Middle East & Africa HER2 Breast Cancer Test Market Attractiveness, by Test Type, 2021–2031
Figure 44: Middle East & Africa HER2 Breast Cancer Test Market Value Share Analysis, by End-user, 2020 and 2031
Figure 45: Middle East & Africa HER2 Breast Cancer Test Market Attractiveness, by End-user, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
HER2 Breast Cancer Test Market Trends, 2021-2031
